What''s Driving AtriCure Inc''s Surprising 19% Stock Rally?

AtriCure, Inc. (NASDAQ: ATRC ) recently announced the receipt of an expanded indication for the AtriClip in CE-marked countries in Europe. The product is now indicated for use in patients at high risk of thromboembolism for whom left atrial appendage (LAA) exclusion is warranted. The European Commission''s expanded indication is based on AtriCure''s clinical findings that patients who are at high risk of thromboembolism can experience fewer strokes with AtriClip.The company expects significant growth potential for the use of mechanical appendage closure. More on the News The LAA is a major source of blood clots in patients with atrial fibrillation (Afib), and the AtriClip device series represents a novel approach to electrically isolate, exclude, and ultimately remove the LAA in the course of heart surgery. More than 85 peer-reviewed papers on the short- and long-term safety and effectiveness of AtriClip devices have been published since the device initially went into use in 2007. This amounts to more than 11,000 patients who were investigated in various regions.

AtriCure Expands AtriClip Indication: A Significant Advancement in Stroke Risk Reduction for Atrial Fibrillation Patients In a transformative stride for the treatment of atrial fibrillation (Afib) and related conditions, AtriCure, Inc. (NASDAQ: ATRC), a pioneering force in the realm of surgical therapies, recently announced an expanded indication for its AtriClip devices across CE-marked countries in Europe. This development is a watershed moment not only for AtriCure but also for the broader landscape of cardiovascular health management, especially for patients grappling with the complexities of Afib. The newly approved indication specifically targets patients at heightened risk of thromboembolism, a serious condition where blood clots can lead to strokes, particularly in individuals with Afib. The AtriClip is now recognized as a suitable tool for left atrial appendage (LAA) exclusion in these patients, thereby providing a much-needed intervention aimed at mitigating the associated risks of stroke.

Expanded indication based on an abundance of clinical evidence for AtriClip Devices AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation …

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received an expanded indication for the AtriClip in CE-marked countries in Europe. The product is now indicated for use in patients at high risk of thromboembolism for whom Jetzt den vollständigen Artikel lesen

AtriCure''s AtriClip devices receive expanded CE-Mark for high-risk thromboembolism patients in Europe. Clinical evidence shows reduced stroke events, with over 550,000 patients treated globally. Learn about this breakthrough in cardiac care.

AtriCure Inc (ATRC) Q2 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Positive Cash Flow Amid Increased Expenses

Q2 2024 AtriCure Inc Earnings Call Transcript

No summary available.

AtriCure (NASDAQ: ATRC ) just reported results for the second quarter of 2024. AtriCure reported earnings per share of -17 cents. This met the analyst estimate for EPS of -17 cents. The company reported revenue of $116.27 million. This was 0.08% better than the analyst estimate for revenue of $116.18 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace Legendary Investor Predicts: “Forget AI… THIS Technology Is the Future” The post ATRC Stock Earnings: AtriCure Meets EPS, Beats Revenue for Q2 2024 appeared first on InvestorPlace .